Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Business Wire•10/11/2026•16:01 ET
0
Key Highlights
- ➤Seralutinib NDA submitted to FDA in September 2026 for PAH
- ➤FDA acceptance could unlock up to approximately $125 million additional capital
- ➤Cash, equivalents and marketable securities totaled $51.2 million September 30
- ➤Quarterly collaborator revenue rose to $38.4 million from $13.3 million
- ➤Net loss was $48.1 million, or $7.36 per share
Expert Statements
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio
“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio
“Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch.”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio
“We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
– New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 –
Get started
Create a free account to read the full story.